Cumberland Pharmaceuticals Inc. (CPIX) — Financial statements
Income statement, balance sheet, and cash flow for Cumberland Pharmaceuticals Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 45↑17.6% | 38↓4.3% | 40↓5.9% | 42↑16.7% | 36 | |
| Cost of Revenue | 7↑1.2% | 7↑8.6% | 6↓33.5% | 9↑3.5% | 9 | |
| Gross Profit | 38↑21.0% | 31↓6.6% | 33↑1.8% | 33↑21.0% | 27 | |
| Operating Expenses | ||||||
| R&D Expenses | 6↑15.6% | 5↓17.4% | 6↓12.8% | 7↑17.7% | 6 | |
| General & Administrative Expenses | 12↑7.4% | 11↑4.5% | 11↑4.6% | 10↑4.1% | 10 | |
| Selling & Marketing Expenses | 19↑12.2% | 17↓7.7% | 18↑10.7% | 17↑11.0% | 15 | |
| SG&A Expenses | 31↑10.3% | 28↓3.3% | 29↑8.4% | 27↑8.2% | 25 | |
| Other Expenses | 4↓15.0% | 5↓41.4% | 8↑59.9% | 5↑15.9% | 4 | |
| Operating Expenses | 41↑7.8% | 38↓12.4% | 43↑11.5% | 39↑10.7% | 35 | |
| Total Costs & Expenses | 47↑6.8% | 44↓9.8% | 49↑2.9% | 48↑9.3% | 44 | |
| Operating Results | ||||||
| Operating Income | -3↑56.6% | -6↑32.7% | -10↓67.5% | -6↑25.7% | -8 | |
| Depreciation & Amortization | 5↓12.5% | 6↓25.4% | 8↑52.1% | 5↑15.7% | 5 | |
| EBITDA | 2↑1267.1% | 0.18↓92.7% | 2↑646.6% | 0.33↑138.8% | -0.86 | |
| EBIT | -3↑52.4% | -6↓4.3% | -6↓12.5% | -5↑8.6% | -5 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.02↑92.9% | -0.27↑28.9% | -0.38↑21.9% | -0.49↓577.7% | -0.07 | |
| Interest Income | 0.48↑42.5% | 0.33↑16.6% | 0.29↑191.5% | 0.10↑277.3% | 0.03 | |
| Interest Expense | 0.50↓18.1% | 0.61↓9.3% | 0.67↑14.0% | 0.59↑497.8% | 0.10 | |
| Non-Operating Income | 0.00↑100.0% | -0.57↑85.5% | -4↓454.8% | -0.71↑67.9% | -2 | |
| Other Income / Expenses | -0.03↑4.5% | -0.03↓101.0% | 3↑2542.4% | 0.12↓94.1% | 2 | |
| Income Before Tax | -3↑56.3% | -6↓2.9% | -6↓12.6% | -6↓0.3% | -6 | |
| Income Tax Expense | 0.04↑277.6% | -0.02↓149.5% | 0.05↓33.5% | 0.07↑97.3% | 0.03 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -3↑55.5% | -6↓1.8% | -6↓12.0% | -6↓0.9% | -6 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 2 | |
| Net Income | -3↑56.2% | -6↓3.2% | -6↓12.7% | -6↓58.8% | -4 | |
| Bottom-Line Net Income | -3↑56.2% | -6↓3.2% | -6↓12.7% | -6↓58.8% | -4 | |
| EPS (Basic) | -0.19↑58.7% | -0.46↓4.5% | -0.44↓15.8% | -0.38↓58.3% | -0.24 | |
| EPS (Diluted) | -0.19↑58.7% | -0.46↓4.5% | -0.44↓15.8% | -0.38↓58.3% | -0.24 | |
| Weighted Average Shares | 15↑6.4% | 14↓1.7% | 14↓1.8% | 15↓2.3% | 15 | |
| Weighted Average Diluted Shares | 15↑6.4% | 14↓1.7% | 14↓1.8% | 15↓2.3% | 15 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.